"GeoArea_Code","GeoArea_Desc","GoalCode","GoalDesc","TargetCode","TargetDesc","IndicatorCode","IndicatorDesc","IndicatorTier","SeriesCode","SeriesDesc","SeriesRelease","Units_Code","Units_Desc","ReportingType_Code","ReportingType_Desc","Value_2008.0","Value_2009.0","Value_2010.0","Value_2011.0","Value_2012.0","Value_2013.0","Value_2014.0","Value_2015.0","Value_2016.0","Latest_Year","Latest_Value","Nature_Desc","Source"
"1","World","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","4","7","11","15","19","26","32","37","42",2016.0,"42","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"2","Africa","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","0","0","3","11","20","33","48","55","62",2016.0,"62","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"5","South America","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","0","1","22","55","71","79","81","85","83",2016.0,"83","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"9","Oceania","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","43","53","53","54","54","56","57","65","67",2016.0,"67","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"11","Western Africa","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","0","0","1","6","11","14","26","39","50",2016.0,"50","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"13","Central America","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","10","33","70","83","85","78","88","92","91",2016.0,"91","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"14","Eastern Africa","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","0","0","3","15","28","55","71","74","77",2016.0,"77","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"15","Northern Africa","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","0","0","0","3","9","16","33","33","44",2016.0,"44","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"17","Middle Africa","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","0","0","0","8","20","33","55","63","65",2016.0,"65","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"18","Southern Africa","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","0","8","49","52","61","61","66","76","72",2016.0,"72","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"19","Americas","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","28","34","51","69","77","79","83","85","84",2016.0,"84","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"21","Northern America","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","88.7891","89.37687","89.99677","91.56223","90.32885","90.85021","91.7608","91.76517","91.77348",2016.0,"91.77348","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"29","Caribbean","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","0","0","0","0","2","3","12","11","13",2016.0,"13","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"30","Eastern Asia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","0","0","0","0","0","0","0","8","8",2016.0,"8","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"34","Southern Asia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","0","0","0","0","0","9","11","16","21",2016.0,"21","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"35","South-Eastern Asia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","0","0","0","0","0","0","8","7","13",2016.0,"13","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"39","Southern Europe","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","22","24","26","30","35","37","41","43","43",2016.0,"43","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"53","Australia and New Zealand","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","74.84975","90.29824","90.65351","91.17102","91.16912","91.33507","91.33242","93.00013","93.83517",2016.0,"93.83517","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"54","Melanesia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","0","0","0","0","0","6","7","26","29",2016.0,"29","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"57","Micronesia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","0","9","30","30","32","49","55","71","68",2016.0,"68","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"61","Polynesia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","0","0","0","0","0","0","0","0","0",2016.0,"0","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"62","Central and Southern Asia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"97","European Union","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"127","Southern Asia (excluding India)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"135","Caucasus and Central Asia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","0","0","0","0","8","11","18","26","69",2016.0,"69","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"142","Asia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","0","3","3","3","4","9","11","16","20",2016.0,"20","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"143","Central Asia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","0","0","0","0","9.22623","12.90227","14.30096","18.11746","64.66682",2016.0,"64.66682","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"145","Western Asia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","1","38","38","48","52","55","57","58","59",2016.0,"59","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"150","Europe","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","12","18","37","40","43","43","45","45","54",2016.0,"54","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"151","Eastern Europe","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","0","2","3","6","6","6","6","7","26",2016.0,"26","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"154","Northern Europe","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","10","18","82","87","88","89","90","90","91",2016.0,"91","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"155","Western Europe","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","25","40","77","77","84","85","85","85","85",2016.0,"85","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"158","Other non-specified areas","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"199","Least Developed Countries (LDCs)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","0","0","1","7","15","30","52","63","72",2016.0,"72","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"202","Sub-Saharan Africa","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","0","0","3","12","22","36","51","59","65",2016.0,"65","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"223","Eastern Asia (excluding Japan and China)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"369"," Iraq (Central Iraq) ","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"419","Latin America and the Caribbean","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","2.99945","10.72789","35.48784","60.30619","71.20318","73.69062","78.87612","82.23396","80.90851",2016.0,"80.90851","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"420","Latin America","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"432","Landlocked developing countries (LLDCs)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","0","0","2","8","23","31","53","60","70",2016.0,"70","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"485","Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","86","87","87","86","81","82","81","79","81",2016.0,"81","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"513","Europe and Northern America","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"514","Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","37","41","52","55","56","57","58","66","71",2016.0,"71","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"515","Developing regions","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","80","83","84","84","84","84","84","84","85",2016.0,"85","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"518","Eastern Asia (excluding Japan)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","97","99","99","99","99","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"535","Bonaire, Sint Eustatius and Saba","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"543","Oceania (exc. Australia and New Zealand)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"722","Small island developing States (SIDS)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","0","1","1","3","5","8","13","17","23",2016.0,"23","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"738","Sub-Saharan Africa (inc. Sudan)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","70","73","72","72","72","72","74","73","74",2016.0,"74","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"746","Northern Africa (exc. Sudan)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","97","97","97","96","95","97","95","95","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"747","Northern Africa and Western Asia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"753","Eastern and South-Eastern Asia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"827","United Kingdom (England and Wales)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"828","United Kingdom (Northern Ireland)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"829","United Kingdom (Scotland)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"830","Channel Islands","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"891","Serbia and Montenegro [former]","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"910","High income economies (WB)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"911","Low income economies (WB)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"912","Lower middle economies (WB)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"913","Low and middle income economies (WB)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"914","Upper middle economies (WB)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"917","International Centers (FAO)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"918","European Union (EU) Institutions","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"919","Regional Centres (FAO)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"920","Azores Islands","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
"921","ODA residual","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","",""
